Summary
57.14 0.41(0.72%)07/08/2024
Catalent Inc. (CTLT)
Catalent Inc. (CTLT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.69 | 1.70 | 1.79 | 0.78 | 22.46 | 25.39 | 4.75 | 185.84 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 57.14 | |
| Open | 56.75 | |
| High | 57.19 | |
| Low | 56.66 | |
| Volume | 840,553 | |
| Change | 0.39 | |
| Change % | 0.69 | |
| Avg Volume (20 Days) | 1,254,528 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 31.80 - 60.20 | |
| Price vs 52 Week High | -5.08% | |
| Price vs 52 Week Low | 79.69% | |
| Range | 0.69 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 10,267 | |
| EBIDTA | 355,000,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 2.0565 | |
| WallStreet Target Price | 56.70 | |
| Book Value | 19.9600 | |
| Earnings Per Share | -6.4800 | |
| EPS Estimate Current Quarter | 0.2100 | |
| EPS Estimate Next Quarter | 0.6400 | |
| EPS Estimate Current Year | 0.3700 | |
| EPS Estimate Next Year | 1.2500 | |
| Diluted EPS (TTM) | -6.4800 | |
| Revenues | ||
| Profit Marging | -0.2844 | |
| Operating Marging (TTM) | 0.0056 | |
| Return on asset (TTM) | -0.0071 | |
| Return on equity (TTM) | -0.2829 | |
| Revenue TTM | 4,135,000,064 | |
| Revenue per share TTM | 22.7510 | |
| Quarterly Revenue Growth (YOY) | 0.0360 | |
| Quarterly Earnings Growth (YOY) | -0.1540 | |
| Gross Profit (TTM) | 1,040,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 37.8788 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.7598 | |
| Revenue Enterprise Value | 3.6507 | |
| EBITDA Enterprise Value | -19.8416 | |
| Shares | ||
| Shares Outstanding | 180,980,000 | |
| Shares Float | 179,960,932 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.05 | |
| Insider (%) | 0.50 | |
| Institutions (%) | 105.26 | |
06/21 13:52 EST - benzinga.com
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
06/07 12:36 EST - zacks.com
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
05/29 09:21 EST - reuters.com
Catalent stockholders approve deal with Novo Holdings
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
Catalent stockholders approve deal with Novo Holdings
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
05/29 09:07 EST - businesswire.com
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents.
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo Holdings”) will acquire all outstanding shares of Catalent for $63.50 per share in cash (the “Merger”). “Today's outcome represents.
05/29 09:00 EST - businesswire.com
Surely Wines Appoints Brandon Joldersma as New CEO
AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Officer, effective February 2024. Joldersma's appointment coincides with a new fundraising round led by Pure Ventures, with additional investors joining Surely's mission to elevate the alcohol-free and low-alcohol beverage market while expanding its offerings within this burgeoning industry. “I'm hon.
Surely Wines Appoints Brandon Joldersma as New CEO
AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Officer, effective February 2024. Joldersma's appointment coincides with a new fundraising round led by Pure Ventures, with additional investors joining Surely's mission to elevate the alcohol-free and low-alcohol beverage market while expanding its offerings within this burgeoning industry. “I'm hon.
05/13 12:21 EST - zacks.com
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
05/09 14:35 EST - zacks.com
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
05/08 20:31 EST - zacks.com
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24. This compares to loss of $0.09 per share a year ago.
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.24. This compares to loss of $0.09 per share a year ago.
05/08 11:00 EST - globenewswire.com
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials.
05/03 08:58 EST - reuters.com
US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.
US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.
04/25 12:45 EST - zacks.com
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better value opportunity right now?
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better value opportunity right now?
04/17 20:19 EST - businesswire.com
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
SAN DIEGO--(BUSINESS WIRE)---- $CTLT #CTLT--Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT).
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
SAN DIEGO--(BUSINESS WIRE)---- $CTLT #CTLT--Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT).
04/17 08:00 EST - investors.com
Here's Your Second Chance To Own 7 Leading Stocks Like Nvidia
Tired of listening to your neighbors bragging about all their winning S&P 500 stocks. You just got another shot at some.
Here's Your Second Chance To Own 7 Leading Stocks Like Nvidia
Tired of listening to your neighbors bragging about all their winning S&P 500 stocks. You just got another shot at some.
04/08 06:31 EST - reuters.com
Novo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.
Novo Nordisk parent refiles US application on Catalent deal
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.
04/02 13:54 EST - businesswire.com
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates. Dr. Roland Green, CEO of Invenra, remarks, “W.
Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates. Dr. Roland Green, CEO of Invenra, remarks, “W.
03/29 09:59 EST - seekingalpha.com
International Companies Drive Diabesity Innovation
International Companies Drive Diabesity Innovation
International Companies Drive Diabesity Innovation
International Companies Drive Diabesity Innovation
03/12 06:25 EST - youtube.com
Novo Owner's CEO on Obesity Sales Boom, Catalent Deal
Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company's deal strategy.
Novo Owner's CEO on Obesity Sales Boom, Catalent Deal
Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company's deal strategy.
03/11 20:22 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
03/07 10:31 EST - reuters.com
Novo Nordisk expects Catalent deal to close later this year
Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.
Novo Nordisk expects Catalent deal to close later this year
Novo Nordisk expects to close its acquisition of Catalent later this year, its chief financial officer said during the company's capital markets day on Thursday, adding that Novo's gross margin is seen falling in the coming years.
03/07 08:00 EST - businesswire.com
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent's corporate responsibility strategy – People, Environment, and Community. The report also outlines the company's future commitments as it progresses its mission to help people lead better and healthier lives. O.
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent's corporate responsibility strategy – People, Environment, and Community. The report also outlines the company's future commitments as it progresses its mission to help people lead better and healthier lives. O.